{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:39:55Z","timestamp":1791430795988,"version":"4.3.3"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.critrevonc.2025.104868","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T15:01:01Z","timestamp":1753542061000},"page":"104868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["IHC-based molecular classification in muscle-invasive urothelial bladder carcinoma: Prognostic and predictive value toward a clinically applicable IHC marker panel \u2013 A systematic review"],"prefix":"10.1016","volume":"214","author":[{"given":"Andrada-Claudia","family":"T\u0103tar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrada","family":"Loghin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adela","family":"Nechifor-Boil\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrada","family":"Raicea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-C\u0103t\u0103lina","family":"Popelea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Borda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2025.104868_bib1","first-page":"15","article-title":"The value and limitations of urothelial bladder carcinoma molecular classifications to predict oncological outcomes and cancer treatment response: a systematic review and meta-analysis","volume":"39","author":"Kardoust Parizi","year":"2021","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.critrevonc.2025.104868_bib2","unstructured":"J.A.C.E. Witjies, N.C. Cowan, G. Gakis, T. Lebret, A.G. Heijden, and M.J. Ribal, Muscle-invasive and metastatic bladder cancer.\u201d Accessed: Jan. 19, 2025. [Online]. Available: \u3008http:\/\/uroweb.org\/guideline\/bladder-cancer-muscle-invasive-and-metastatic\/#1\u3009."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104868_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pathol.2020.09.004","article-title":"Urothelial carcinoma: variant histology, molecular subtyping, and immunophenotyping significant for treatment outcomes","volume":"53","author":"Takahara","year":"2021","journal-title":"Pathology"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104868_bib4","first-page":"404","article-title":"Treatment of muscle-invasive and advanced bladder cancer in 2020","volume":"70","author":"Patel","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104868_bib5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.euf.2020.01.007","article-title":"Management of muscle-invasive bladder cancer in the 2020s: challenges and perspectives","volume":"6","author":"Gakis","year":"2020","journal-title":"Eur. Urol. Focus"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104868_bib6","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder cancer, version 3.2020, NCCN clinical practice guidelines in oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104868_bib7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104868_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100296","article-title":"Circulating miRNAs in genitourinary cancer: pioneering advances in early detection and diagnosis","volume":"8","author":"Cicatiello","year":"2025","journal-title":"J. Liq. Biopsy"},{"key":"10.1016\/j.critrevonc.2025.104868_bib9","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104868_bib10","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2025.104868_bib11","unstructured":"CASP Cohort Study Checklist.\u201d Accessed: Jun. 10, 2025. [Online]. Available: \u3008https:\/\/casp-uk.net\/casp-tools-checklists\/cohort-study-checklist\/\u3009."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104868_bib12","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.3390\/cancers12071784","article-title":"Immunohistochemistry-based taxonomical classification of bladder cancer predicts response to neoadjuvant chemotherapy","volume":"12","author":"Font","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104868_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4111\/icu.20200425","article-title":"Association of immunohistochemical markers of tumor subtype with response to neoadjuvant chemotherapy and survival in patients with muscle-invasive bladder cancer","volume":"62","author":"Razzaghdoust","year":"2021","journal-title":"Invest. Clin. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104868_bib14","article-title":"<scp>Triple-marker<\/scp> immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?","volume":"4","author":"Labban","year":"2021","journal-title":"Cancer Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104868_bib15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/ijms22020628","article-title":"Comprehensive gene expression analyses of immunohistochemically defined subgroups of muscle-invasive urinary bladder urothelial carcinoma","volume":"22","author":"Kim","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104868_bib16","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1007\/s00345-021-03788-1","article-title":"Prognostic impact of molecular muscle-invasive bladder cancer subtyping approaches and correlations with variant histology in a population-based mono-institutional cystectomy cohort","volume":"39","author":"Weyerer","year":"2021","journal-title":"World J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104868_bib17","doi-asserted-by":"crossref","DOI":"10.6061\/clinics\/2021\/e2587","article-title":"Combined use of immunohistochemical markers of basal and luminal subtypes in urothelial carcinoma of the bladder: Association with clinicopathological features and outcomes","volume":"76","author":"Ravanini","year":"2021","journal-title":"Clinics"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104868_bib18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/pin.13060","article-title":"Comprehensive pathological assessment of histological subtypes, molecular subtypes based on immunohistochemistry, and tumor-associated immune cell status in muscle-invasive bladder cancer","volume":"71","author":"Ikeda","year":"2021","journal-title":"Pathol. Int"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104868_bib19","doi-asserted-by":"crossref","first-page":"21186","DOI":"10.1038\/s41598-021-00628-5","article-title":"Impact of immunohistochemistry-based subtyping of GATA3, CK20, CK5\/6, and CK14 expression on survival after radical cystectomy for muscle-invasive bladder cancer","volume":"11","author":"Bejrananda","year":"2021","journal-title":"Sci. Rep."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104868_bib20","doi-asserted-by":"crossref","first-page":"4911","DOI":"10.3390\/cancers14194911","article-title":"Development of a clinically applicable nanostring-based gene expression classifier for muscle-invasive bladder cancer molecular stratification","volume":"14","author":"Olkhov-Mitsel","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104868_bib21","article-title":"CK5\/6 and GATA3 defined phenotypes of muscle-invasive bladder cancer: impact in adjuvant chemotherapy and molecular subtyping of negative cases","volume":"9","author":"Koll","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104868_bib22","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4103\/ijpm.ijpm_95_21","article-title":"Molecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlation","volume":"65","author":"Gupta","year":"2022","journal-title":"Indian J. Pathol. Microbiol"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104868_bib23","doi-asserted-by":"crossref","first-page":"7430","DOI":"10.3390\/jcm11247430","article-title":"Immunohistochemical algorithm for the classification of muscle-invasive urinary bladder carcinoma with lymph node metastasis: an institutional study","volume":"11","author":"Pe\u00f1a","year":"2022","journal-title":"J. Clin. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104868_bib24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.21037\/tau-22-538","article-title":"Identification and validation of immunohistochemical marker panels to predict the prognosis of muscle invasive bladder cancer","volume":"12","author":"Ying","year":"2023","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.critrevonc.2025.104868_bib25","doi-asserted-by":"crossref","DOI":"10.17305\/bb.2023.9242","article-title":"Molecular classification of muscle-invasive bladder cancer based on a simplified immunohistochemical panel using GATA3, CK5\/6 and p16","author":"Terlevi\u0107","year":"2023","journal-title":"Biomol. Biomed."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104868_bib26","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.3390\/ijms24076610","article-title":"Clinicopathological features and survival analysis in molecular subtypes of muscle-invasive bladder cancer","volume":"24","author":"Sanguedolce","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104868_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13000-023-01295-y","article-title":"Immunohistochemical based molecular subtypes of muscle-invasive bladder cancer: association with HER2 and EGFR alterations, neoadjuvant chemotherapy response and survival","volume":"18","author":"Helal","year":"2023","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104868_bib28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euros.2023.09.003","article-title":"Feasibility and impact of immunohistochemistry-based molecular subtyping for muscle-invasive bladder cancer in patients treated with radiation-based therapy","volume":"57","author":"Hesswani","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"10.1016\/j.critrevonc.2025.104868_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2023.104860","article-title":"Cytokeratin 20 expression is linked to stage progression and to poor prognosis in advanced (pT4) urothelial carcinoma of the bladder","volume":"131","author":"Bruch","year":"2023","journal-title":"Exp. Mol. Pathol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104868_bib30","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.31557\/APJCP.2024.25.11.3953","article-title":"Identification of Molecular Subgroups of Muscle-Invasive Urothelial Bladder Cancer and Their Impact on Treatment Outcome","volume":"25","author":"Rashad","year":"2024","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104868_bib31","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.eururo.2015.02.021","article-title":"A molecular pathologic framework for risk stratification of stage T1 urothelial carcinoma","volume":"68","author":"Patschan","year":"2015","journal-title":"Eur. Urol."},{"issue":"40","key":"10.1016\/j.critrevonc.2025.104868_bib32","doi-asserted-by":"crossref","first-page":"67684","DOI":"10.18632\/oncotarget.18804","article-title":"Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies","volume":"8","author":"Breyer","year":"2017","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104868_bib33","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/1066896919830509","article-title":"Molecular pathologic subtyping of urothelial bladder carcinoma in young patients","volume":"27","author":"Shelekhova","year":"2019","journal-title":"Int J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104868_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00428-017-2064-8","article-title":"In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival","volume":"470","author":"Breyer","year":"2017","journal-title":"Virchows Arch."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104868_bib35","doi-asserted-by":"crossref","first-page":"e712","DOI":"10.1016\/j.clgc.2019.04.011","article-title":"A simple immunohistochemical panel could predict and correlate to clinicopathologic and molecular subgroups of urinary bladder urothelial carcinoma","volume":"17","author":"Makboul","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"issue":"40","key":"10.1016\/j.critrevonc.2025.104868_bib36","doi-asserted-by":"crossref","first-page":"25935","DOI":"10.18632\/oncotarget.25407","article-title":"Subclassification, survival prediction and drug target analyses of chemotherapy-na\u00efve muscle-invasive bladder cancer with a molecular screening","volume":"9","author":"Rinaldetti","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104868_bib37","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13073-019-0669-z","article-title":"Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis","volume":"11","author":"de Jong","year":"2019","journal-title":"Genome Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104868_bib38","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","article-title":"The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability","volume":"75","author":"Kim","year":"2019","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104868_bib39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1159\/000281888","article-title":"Epithelial membrane antigen as an immunohistochemical marker for transitional cell carcinoma of the urinary bladder","volume":"42","author":"Takashi","year":"1987","journal-title":"Urol. Int"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104868_bib40","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2025.104868_bib41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2016.08.036","article-title":"Meta-analysis of the luminal and basal subtypes of bladder cancer and the identification of signature immunohistochemical markers for clinical use","volume":"12","author":"Dadhania","year":"2016","journal-title":"EBioMedicine"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104868_bib42","first-page":"675.e1","article-title":"Sialyl-Tn identifies muscle-invasive bladder cancer basal and luminal subtypes facing decreased survival, being expressed by circulating tumor cells and metastases","volume":"35","author":"Lima","year":"2017","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"10.1016\/j.critrevonc.2025.104868_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.humpath.2019.07.002","article-title":"The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5\/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder","volume":"91","author":"Calvete","year":"2019","journal-title":"Hum. Pathol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104868_bib44","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1073\/pnas.1120605109","article-title":"Three differentiation states risk-stratify bladder cancer into distinct subtypes","volume":"109","author":"Volkmer","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104868_bib45","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85902","article-title":"Claudin-low bladder tumors are immune infiltrated and actively immune suppressed","volume":"1","author":"Kardos","year":"2016","journal-title":"JCI Insight"},{"issue":"244","key":"10.1016\/j.critrevonc.2025.104868_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008970","article-title":"EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype","volume":"6","author":"Rebouissou","year":"2014","journal-title":"Sci. Transl. Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104868_bib47","doi-asserted-by":"crossref","first-page":"35854","DOI":"10.1038\/srep35854","article-title":"Basal tumor cell isolation and patient-derived xenograft engraftment identify high-risk clinical bladder cancers","volume":"6","author":"Skowron","year":"2016","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104868_bib48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104868_bib49","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur. Urol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104868_bib50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1158\/2326-6066.CIR-18-0758","article-title":"The tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes","volume":"7","author":"Pfannstiel","year":"2019","journal-title":"Cancer Immunol. Res"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104868_bib51","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104868_bib52","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1038\/s41598-020-66747-7","article-title":"Assessment of luminal and basal phenotypes in bladder cancer","volume":"10","author":"Guo","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.104868_bib53","series-title":"in Modern Approach to Diagnosis and Treatment of Bladder Cancer","article-title":"Molecular Classification of Bladder Cancer","author":"Kaushal","year":"2021"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104868_bib54","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1097\/PAS.0000000000001453","article-title":"Report from the international society of urological pathology (ISUP) consultation conference on molecular pathology of urogenital cancers. ii. molecular pathology of bladder cancer","volume":"44","author":"Warrick","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.critrevonc.2025.104868_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100305","article-title":"Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions","volume":"9","author":"Crocetto","year":"2025","journal-title":"J. Liq. Biopsy"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104868_bib56","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/path.5230","article-title":"Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts","volume":"247","author":"Sj\u00f6dahl","year":"2019","journal-title":"J. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104868_bib57","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/his.13696","article-title":"Basal-subtype bladder tumours show a \u2018hot\u2019 immunophenotype","volume":"73","author":"Hodgson","year":"2018","journal-title":"Histopathology"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825002562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T01:18:07Z","timestamp":1758590287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825002562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":57,"alternative-id":["S1040842825002562"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104868","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IHC-based molecular classification in muscle-invasive urothelial bladder carcinoma: Prognostic and predictive value toward a clinically applicable IHC marker panel \u2013 A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104868","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104868"}}